Atossa Therapeutics Analyst Ratings
Atossa Therapeutics Analyst Ratings
While ratings are subjective and will change, the latest Atossa Therapeutics (ATOS) rating was a initiated with a price target of $0.00 to $5.00. The current price Atossa Therapeutics (ATOS) is trading at is $0.74, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/08/2023 | 572.49% | Cantor Fitzgerald | → $5 | Initiates Coverage On | → Overweight |
| 09/17/2020 | 841.49% | Ascendiant Capital | → $7 | Initiates Coverage On | → Buy |
| 12/18/2019 | — | Maxim Group | Upgrades | Hold → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 09/08/2023 | 572.49% | 康託·菲茨傑拉德 | →$5 | 開始承保 | →超重 |
| 09/17/2020 | 841.49% | 《上升之都》 | →$7 | 開始承保 | →購買 |
| 2019年12月18日 | - | Maxim集團 | 升級 | 持有→購買 |
What is the target price for Atossa Therapeutics (ATOS)?
Atossa治療公司(ATOS)的目標價格是多少？
The latest price target for Atossa Therapeutics (NASDAQ: ATOS) was reported by Cantor Fitzgerald on September 8, 2023. The analyst firm set a price target for $5.00 expecting ATOS to rise to within 12 months (a possible 572.49% upside). 1 analyst firms have reported ratings in the last year.
坎託·菲茨傑拉德於2023年9月8日報道了Atossa治療公司(納斯達克：ATOS)的最新目標價。這家分析公司將目標價定為5美元，預計Atos將在12個月內上漲至(可能上漲572.49%)。1家分析公司在過去一年公佈了評級。
What is the most recent analyst rating for Atossa Therapeutics (ATOS)?
阿託薩治療公司(ATOS)的最新分析師評級是多少？
The latest analyst rating for Atossa Therapeutics (NASDAQ: ATOS) was provided by Cantor Fitzgerald, and Atossa Therapeutics initiated their overweight rating.
阿託薩治療公司(納斯達克代碼：ATOS)的最新分析師評級由坎託·菲茨傑拉德提供，阿託薩治療公司啟動了他們的增持評級。
When is the next analyst rating going to be posted or updated for Atossa Therapeutics (ATOS)?
Atossa治療公司(ATOS)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Atossa Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Atossa Therapeutics was filed on September 8, 2023 so you should expect the next rating to be made available sometime around September 8, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與Atossa治療公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Atossa治療公司的上一次評級是在2023年9月8日提交的，所以你應該預計下一次評級將在2024年9月8日左右提供。
Is the Analyst Rating Atossa Therapeutics (ATOS) correct?
分析師對Atossa Treeutics(ATOS)的評級正確嗎？
While ratings are subjective and will change, the latest Atossa Therapeutics (ATOS) rating was a initiated with a price target of $0.00 to $5.00. The current price Atossa Therapeutics (ATOS) is trading at is $0.74, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Atossa治療公司(ATOS)評級是以0.00美元至5.00美元的目標價啟動的。Atossa治療公司(ATOS)目前的交易價格為0.74美元，在分析師的預測範圍內。
譯文內容由第三人軟體翻譯。
